Presentations & Publications

Division of Transplantation

Recent Presentations:

Cavanaugh TM, Martin JE, Culp V, Parrish N, Rudich S, Neff GW:  “Evaluating the clinical impact of a change in tacrolimus immunoassay.”  International Congress of the Transplantation Society, Sydney, Australia, August 2008.

Clarke CN, Quillin RC, Wang J, Kim DS, Edwards M, Woodle ES, Rudich SM, Lentsch AB, Tevar AD:  “Laparoscopic cholecystectomy in the cirrhotic patient.”  American Association for the Study of Liver Diseases, Boston, MA, October 2009. 

Kim DS, Doty TC, Tevar AD, Buell JF, Ristagno RL, Rudich SM:  “Comparison of radiologic and pathologic response following 90Y microspheres therapy for hepatocellular carcinoma.”  American Hepato-Pancreato-Biliary Association, Miami, FL, March 2009.

Klintmalm GB, Fasola CG, Jennings L, Heffron TG, Sher L, Douglas D, Brown R, Ham J, Teperman L, Rudich S, Eckhoff D, Washburn K, Millis M, Robert J, Charlton M, Baliga P, Pruett T, Koneru B, Pomfret E, Abecassis M:  “Hepatitis C 3 Study: Day 90 protocol biopsy grade is a surrogate marker for severe HCV recurrence at years 1 and 2 post liver transplantation.”  European Society of Transplantation, Paris, France, September 2009. 

Klintmalm GB, Fasola CG, Jennings L, Heffron TG, Sher L, Mulligan D, Brown R, Ham J, Teperman L, Rudich S, Eckhoff D, Washburn K, Millis M, Roberts J, Charlton M, Baliga P, Pruett T, Pomfret E, Koneru B, Abecassis M:  “Hepatitis C (HCV)-3 study: Severe HCV recurrence post liver transplantation (OLT) is decreased in patients treated with mycophenolate mofetil (MMF), particularly, in the absence of steroids.” Association for the Study of Liver Diseases, San Francisco, CA, October 2008.

Lui X, Dickson ME, Chatterjee TK, Rudich SM, Weintraub NL, Sigmund CD: “USF1 is required for expression of angiotensinogen on adipose tissue.”  American Heart Association High Blood Pressure Research Conference, Chicago, IL, September 2009. 

Mast TD, Barthe PG, Makin I, Slayton MH, Buell JF, Rudich SM.  Treatment of VX2 tumor in vivo using miniaturized image-ablate arrays.  American Institute of Ultrasound in Medicine, New York, NY, April 2009.

Mast TD, Barthe PG, Makin IR, Slayton MH, Karunakaran CP, Burgess MT, Alqadah AF, Buell JF, Rudich SM: “In-vivo treatment of rabbit VX2 tumor by miniaturized image-ablate ultrasound arrays.”  IEEE International Ultrasonics Symposium, Roma Italy, September 2009.

Rudich SM: “The surgical approach for the patient with a liver mass.”  The Fifth Annual Midwest Liver Forum, University of Cincinnati, Mason, OH, August 2009.

Rudich SM: “Liver transplant surgery and complications; graft function.”  Program for the Advancement of Clinical Excellence in Transplant Nursing, University Hospital, Cincinnati, OH, February 2009.

Rudich SM: “Cancer patients: Patient selection, liver resections vs transplantation.” Life Connection of Ohio, Organ Donation & Transplantation of Abdominal Organs: Donor, Nursing & Recipient Issues-Fall Clinical Forum, Kettering, OH, October 2009.

Rudich SM: “Treatment of VX2 tumor in vivo using miniaturized image-ablate arrays.”  American Institute of Ultrasound in Medicine, New York, NY, April 2009.

Rudich SM: “Multicenter analysis of liver transplantation for metastatic neuroendocrine tumor: Is a MELD exception justified?”  American Transplant Congress, Boston, MA, May 2009.

Rudich SM: “Laparoscopic cholecystectomy in the cirrhotic patient.”  American Association for the Study of Liver Diseases, Boston, MA, October 2009.

Sher L, Levi D, Mulligan D, Shidban S, Solomon H, Miller C, Marsh W, Rudich S, Esquivel C, Shaked A, Fisher R Schwartz M: “Do liver transplant outcomes for neuroendocrine tumors justify MELD exception?” American Association for the Study of Liver Diseases, San Francisco, CA, October 2008.

Weesler J, Mateo R, Levi D, Schwartz M, Marsh W, Miller C, Dickson R, Rudich S, Esquivel C, Mulligan D, Shaked A, Genyk Y, Solomon H, Fisher R, Hong J, Pruett T, Selby R, Sher L:  “Multicenter analysis of liver transplantation for metastatic neuroendocrine tumor: Is a MELD exception justified?”  American Transplant Congress, Boston, MA, May 2009.

Woodle ES:  “Pre and post transplant malignancy.”  University of Minnesota, Transplant Grand Rounds, Minneapolis, MN, July 2008.

Woodle ES:  “Development of plasma cell targeted therapies for humorally medicated immunity in humans.”  Yale University, Transplant Grand Rounds, New Haven, CT, July 2008.

Woodle ES:  “A 12-month, prospective, randomized, single center, open pilot study to evaluate the safety and efficacy of myfortic in combination with tacrolimus and thymoglobulin in early corticosteroid withdrawal.”  International Congress of the Transplantation Society, Sydney, Australia, August 2008.

Woodle ES:  “African-American kidney txp recipients undergoing early corticosteroid withdrawal: Long term (5 yr) results similar to non-African-Americans.”  International Congress of the Transplantation Society, Sydney, Australia, August 2008.

Woodle ES:  “YSPSL (rPSGL-lg) for the prevention of delayed graft function (DGF): Results of double-blind, placebo-controlled, multi-center phase I/II safety and efficacy study.”  International Congress of the Transplantation Society, Sydney, Australia, August 2008.

Woodle ES:  “A multi-center, randomized, double-blind, placebo-controlled trial of early corticosteroid cessation: Final five year report.”  International Congress of the Transplantation Society, Sydney, Australia, August 2008.

Woodle ES:  “12-Month results of multicenter, randomized trial comparing three induction agents (alemtuzumab, thymoglobulim and basiliximab) with tacrolimus mycophenolate mofetil and rapid steroid withdrawal in renal transplantation.”  International Congress of the Transplantation Society, Sydney, Australia, August 2008.

Woodle ES:  “Long-term result with CNI minimization and corticosteroid avoidance.”  Multi-Organ Transplant Grand Rounds, Dalhousie University, Halifax, Nova Scotia, September 2008.

Woodle ES:  “A transplanter transplanted.”  Temple University, Transplant Grand Rounds, Philadelphia, PA, September 2008.

Woodle ES:  “Transplantation: A patient’s perspective.”  First Annual Symposium on Kidney Disease, Crozer-Keystone Health Systems and Temple University Health System, Springfield, PA, September 2008.

Woodle ES:  “Cancer and transplantation: Candidacy, treatment, and transmission risk.”  Long-Term Management of the Transplant Recipient Conference, Henry Ford Transplant Institute, Detroit, MI, October 2008.

Woodle ES:  “New strategies and therapeutic advances in renal transplantation: A best practices program for improved patient outcomes.”  Geissinger Medical Center, Wilkes-Barre, PA, October 2008.

Woodle ES:  “New strategies and therapeutic advances in renal transplantation: A best practices program for improved patient outcomes.”  St. Johns Hospital, Detroit, MI, November 2008.

Woodle ES:  “Paired kidney donation: State of rapidly changing art.”  Starzl Institute, Transplant Grand Rounds, University of Pittsburgh Medical Center, Pittsburgh, PA, November 2008.

Woodle ES:  “New strategies and therapeutic advances in renal transplantation: A best practices program for improved patient outcomes.”  Avera McKenna Transplant Institute, Sioux Falls, SD, December 2008.

Woodle ES:  “Ethics of chain paired donation and non-directed donor initiated paired kidney donation.”  Paired Donation Consortium, Orlando, FL, December 2008.

Woodle ES:  “Immunosuppression minimization in kidney transplantation.”  Des Moines Mercy Hospital Transplant Center, Des Moines, IA, December 2008.

Woodle ES:  “New strategies and therapeutic advances in renal transplantation: A best practices program for improved patient outcomes.”  Emory University School of Medicine, Atlanta, GA, January 2009.

Woodle ES:  “Corticosteroid elimination: Past, present, and future.”  University of Alberta, Edmonton, Alberta, Canada, January 2009.

Woodle ES:  “Corticosteroid elimination: Past, present, and future.”  University of Calgary, Calgary, Alberta, Canada, January 2009.

Woodle ES:  “Corticosteroid elimination: Past, present, and future.”  University of British Columbia, Vancouver, British Columbia, Canada, January 2009.

Woodle ES:  “CNI and corticosteroid minimization.”  Baylor All Saints Medical Center, Fort Worth, TX, January 2009.

Woodle ES:  “New strategies and therapeutic advances in renal transplantation: A best practices program for improved patient outcomes.”  University of South Carolina Medical School, Charleston, SC, January 2009.

Woodle ES:  “5 year results of the U.S. double blind steroid withdrawal study in renal transplantation.”  University of Toronto, Toronto, Ontario, Canada, February 2009.

Woodle ES:  “Randomized controlled trial of campath in renal transplant recipients.”  Multi Organ Transplant Rounds, University of Toronto, Toronto, Ontario, Canada, February 2009.

Woodle ES:  “Ethical issues surrounding paired donation and altruistic donors.”  Paired Donation Network 3rd Annual Meeting, Orlando, FL, February 2009.

Woodle ES:  “Evidence-based decision making in transplantation oncology.”  Columbia University College of Physicians and Surgeons, New York, NY, March 2009.

Woodle ES:  “Proteasome inhibition: Basic science and clinical experience.” University of Miami School of Medicine, Miami, FL, July 2009.

Woodle ES:  “History of immunosuppressive therapy-renal transplantation.” North American Transplant Coordinators Annual Meeting, Las Vegas, NV, August 2009.

Woodle ES:  “Pre-transplant malignancy.”  University of Minnesota, Minneapolis, MN, September 2009.

Woodle ES:  “Bortezomib therapy for acute humoral rejection.”  14th Congress of the European Society for Organ Transplantation, Paris, France, September 2009.

Woodle ES:  “Steroid-free immunosuppression: Randomized Trials.”  University of Minnesota, Minneapolis, MN, September 2009.

Woodle ES:  “Proteasome inhibition-based anti-humoral therapy in transplantation.”  Cambridge, MA, October 2009.

Woodle ES:  “Plasma cells, proteasomes, protein folding and programmed cell death.”  University of Texas, Houston, TX, October 2009. 

Recent Publications:

Alexander JW, Light JA, James JH, Goodman HR, Kuo PC, Woodle ES, Succop P, Moser AB.  Influence of long chain polyunsaturated fatty acids and ornithine concentrations on complications after renal transplantation.  Exper Clin Transplant 2:118-126, 2008.

Chatterjee TK, Stoll LL, Denning GM, Harrelson A, Romig-Martin SA, Dickson EW, Rudich SM, Weintraub NL.  Pro-inflammatory phenotype of perivascular adipocytes: Influence of high-fat feeding.  Circulation Res 104:541-549, 2009.

Chen Y, Trofe J, Gordon J, Autissier P, Woodle ES, Koralnik IJ.  BKV and JCV large T antigen-specific CD8+ T cell response in HLA A*0201+ kidney transplant recipients with polymavirus nephropathy and patients with progressive multifocal leukoencephalopahty.  J Clin Virol 42:198-202, 2008.

Devita MA, Brooks MM, Zawistowski C, Rudich SM, Daly B, Chaitin E.  Donors after cardiac death: Validation of identification criteria (DVIC) study for predictors of rapid death.  Am J Transplant 8:432-441, 2008.

Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Rike AH, Cardi M, Wadith G, Tevar A, Woodle ES.  Bortezomib provides effective therapy for anti-body and cell-mediated acute rejection.  Transplantation 86(12):1754-1761, 2008.

Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Rike AH, Cardi M, Wadih G, Brown E, Tevar A, Woodle ES.  Proteasome inhibition reduces donor-specifc antibody levels.  Transplant Proc 41(1):105-107, 2009.

Everly MJ, Everly JJ, Arend LJ, Brailey P, Susskind B, Govil A, Rike A, Roy-Chaudhury P, Mogilishetty G, Alloway R, Tevar A, Woodle ES.  Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss.  Am J Transplant, in press, 2009.

Kauffman HM, Woodle ES, Cole EH, Paykin C.  Transplant recipient’s knowledge of post-transplant malignancy risk: Implications for educational programs.  Transplantation 85(7):928-933, 2008.

Krishnamoorthy M, Roy-Chaudhury P, Wang Y, Roy AS, Zhang J, Khoury S, Munda R, Banerjee R.  Measurement of hemodynamic and anatomic parameters in a swine arteriovenous fistula model: A technical note with possibilities for the future.  J Vasc Access 9:28-34, 2008.

Martin JE, Cavanaugh TM, Trumbull L, Bass M, Weber F, Aranda-Michel J, Hanaway M, Rudich S.  Incidence of adverse events with HMG-CoA reductase inhibitors in liver transplant patients.  Clinical Transplant 22:113-119, 2008.

Mast TD, Pucke DP, Subramanian SE, Bowlus WJ, Rudich SM, Buell JF.  Ultrasonic monitoring of in vitro radiofrequency ablation by echo decorrelation imaging.  J Ultrasound Med 27:1685-1697, 2008.

Miao Y, Everly MJ, Gross TG, Tevar AD, First MR, Alloway RR, Woodle ES.  De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared to the general population.  Transplantation, in press, 2009.

Rike AH, Mogilishetty G, Alloway RA, Succop P, Roy-Chaudhury P, Cardi M, Kaiser TE, Thomas M, Woodle ES.  Cardiovascular risk, cardiovascular events, and metabolic syndrome in renal transplantation: Comparison of early steroid withdrawal and chronic steroids.  Clin Transplant 22 (2):229-35, 2008.

Roy-Chaudhury P, Wang Y, Krishnamoorthy M, Zhang J, Banerjee R, Munda R, Heffelfinger SC, Arend L. Cellular phenotypes in hemodialysis vascular access dysfunction. Nephrol Dial Transplant 23:525-533, 2008.

Rudich SM, Tevar AD.  Laparoscopic liver resection.  In Fischer JE, Bland B (eds), Mastery of Surgery, 6th Edition.  Lippincott Williams & Wilkins, 2009.

Tevar A, Thompson J, King S, editors.  Deja Review: Surgery. New York: McGraw-Hill, 2009.

Walker JK, Alloway RA, Roy-Chaudhury P, Mogilishetty G, Cardi MA, Weimert NA, Rike AH, First MR, Woodle ES.  A prospective trial of a steroid-free/calcineurin inhibitor minimization regimen in HLA identical live donor renal transplantation.  Transplantation 87:408-414, 2009.

Wang Y, Krishnamoorthy M, Banerjee R, Zhang J, Rudich SM, Holland C, Arend L, Roy-Chaudhury P.  Venous stenosis in a pig arteriovenous fistula anatomy, mechanisms and cellular phenotypes.  Nephrology Dialysis Transplantation 23:525-533, 2008.

Whitaker I, Guggan EM, Alloway RR, Brown C, McGuire S, Woodle ES, Banis JC, Maldonado C, Barker JH.  Composite tissue allotransplantation: A review of relevant immunological issues for plastic surgeons.  J Plastic Reconstruct Aesthetic Surg 61(5):481-492, 2008.

Woodle ES, Alloway R, Rike A, Roy-Chaudhury P, Tevar A, Susskind B, Everly J, Moglishetty G, Brailey P, Govil A, Rudich S, First MR, Alexander JW, Munda R, Cardi M, Arend L.  Corticosteroid elimination: The Cincinnati experience.  In Cecka JM, Terasaki PI (eds), Clinical Transplants 2007. Terasaki Foundation Laboratory, 2008.

Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldheisen P.  A prospective, randomized, double-bind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy.  Ann Surg 248:564-577, 2008.

Woodle ES, Ram Peddi V, Tomlanovich S, Mulgaonkar S, Kuo PC, TRIMS Study Investigators. A randomized, prospective, study comparing early corticosteroid withdrawal under thymoglobulin induction with maintenance corticosteroid therapy in living-donor kidney transplant recipients.  Clinical Transplantation, in press, 2009.

 

Note:  To add a presentation or publication, please email to steve.wiesner@uc.edu.